The purpose of the Animal Genomics Shared Resource (AGS) is to create (and through cryopreservation, maintain) transgenic and knockout models for human diseases including cancer. The specific objectives are: 1) Provide consultation on transgene and targeting construct design;2) Introduce DNA into zygotes or embryonic stem cells;3) Create founder animals or chimeras that incorporate the desired, DNA addition or change;and 4) Cryopreserve mouse embryos for cost-effective, long-term storage of genetically engineered mice. The Transgenic mouse service was created in 1989. The ability to create knockout mice was added in 1997. Cryopreservation of mouse embryos has been performed since 2000. The creation of novel mouse strains, either by transgenesis or homologous recombination, allows many members of the Yale Cancer Center (YCC), to determine the normal function of genes and how perturbation of that function can result in aberrant development or diseases such as cancer. Investigators can use AGS to create direct analogs of mutations involved in human disease, thus providing models that can be studied in a way that human subjects cannot. The ability to create such induced mutants allows investigators to effectively use mouse genetics to dissect and analyze complicated developmental pathways, biochemical processes, and biomolecular interactions in a mammal to a level previously unattainable before such technology existed. This enables researchers to investigate biological processes at a far deeper level than in vitro methods such as biochemistry or cell culture will allow, and through the appearance of novel phenotypes resulting from induced mutations, discover new relationships between these processes and pathways. Cryopreservation of mouse strains allows investigators to more efficiently utilize their financial resources in research while maintaining valuable strains for future use. The YCC AGS produces 40-60 transgenic mouse strains/year, and creates 15-20 new targeted mutant mouse models/year. Animal Genomics Services has been a shared resource of the YCC since 1989. AGS moved into new space designed specifically for their use with the completion of The Anylan Center building in 2002. Twenty-eight YCC investigators used AGS in 2005 for a total of approx. 62% of all usage of the resource. All YCC usage during 2005 was from peer-reviewed scientists from 7 of 8 YCC Research Programs

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-33
Application #
8312358
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
33
Fiscal Year
2011
Total Cost
$179,407
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053
Sarma, Elizabeth A; Kawachi, Ichiro; Poole, Elizabeth M et al. (2018) Social integration and survival after diagnosis of colorectal cancer. Cancer 124:833-840
Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287

Showing the most recent 10 out of 675 publications